James K. C. Liu

H Lee Moffitt Cancer Center and Research Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (15)

Year:

2026

Year:

2026

Brain metastasis occurs in up to 40% of patients with non–small cell lung cancer (NSCLC). Considerable genomic heterogeneity exists between the primary lung tumor and respective brain metastasis; however, the identity of the genes capable of driving brain metastasis is incompletely understood. Here, we carried out an in vivo genome-wide CRISPR activation screen to identify molecular drivers of brain metastasis from an orthotopic xenograft model derived from a patient with NSCLC. We found that activating expression of the Alzheimer’s disease–associated beta-secretase 1 (BACE1) led to a substantial increase in brain metastases. Furthermore, genetic and pharmacological inhibition of BACE1 blocked NSCLC brain metastasis. Mechanistically, we identified that BACE1 acts through epidermal growth factor receptor to drive this metastatic phenotype. Together, our data highlight the power of in vivo CRISPR activation screening to unveil molecular drivers and potential therapeutic targets of NSCLC brain metastasis.

Year:

2025

Supplementary Figure 1. GBM-infiltrating Neutrophils are immunosuppressive cells. Supplementary Figure 2. CD71 identifies a cluster of hypoxic and glycolytic Neutrophils. Supplementary Figure 3. CD71+ Neutrophils are long-lived and mature cells that are found in the hypoxic-glycolytic niches of brain tumors. Supplementary Figure 4. CD71+ Neutrophils are immunosuppressive cells within the GBM TME. Supplementary Figure 5. CD71 expression and the immunosuppressive ability cannot be induced in CD71 − Neutrophils. Supplementary Figure 6. Hypoxic CD71+ Neutrophils are long-lived cells but CD71 is not required for their immunosuppressive ability. Supplementary Figure 7. Hypoxia boosts the glycolytic metabolism of CD71+ Neutrophils. Supplementary Figure 8. Extracellular lactate and histone acetylation are not involved in the regulation of the immunosuppressive ability of hypoxic CD71+ Neutrophils. Supplementary Figure 9. Isosafrole specifically inhibits the immunosuppressive ability of hypoxic CD71+ Neutrophils. Supplementary Figure 10. Human CD71+ neutrophils are glycolytic and immunosuppressive cells.

Year:

2025

Despite functional heterogeneity, the high frequency of intratumoral neutrophils predicts poor clinical outcomes. The tumor microenvironment reprograms neutrophils into immunosuppressive subsets that hinder anticancer immunity, thereby contributing to tumor growth and resistance to immunotherapies. However, the mechanisms underlying neutrophil reprogramming remain elusive. In this study, we report that the immunosuppressive ability of brain tumor–infiltrating neutrophils was restricted to a highly glycolytic and long-lived subset expressing CD71, which acquired immunosuppressive properties in response to hypoxia. Mechanistically, hypoxia boosted glucose metabolism in CD71 + neutrophils, leading to high lactate production. Lactate caused histone lactylation, which subsequently regulated arginase-1 expression, required for T-cell suppression. Targeting histone lactylation with the antiepileptic drug isosafrole blocked CD71 + neutrophil immunosuppressive ability, delayed tumor progression, and sensitized brain tumors to immunotherapy. A distinctive gene signature characterizing immunosuppressive CD71 + neutrophils correlated with adverse clinical outcomes across diverse human malignancies. This study identifies histone lactylation as a potential therapeutic target to counteract neutrophil-induced immunosuppression within tumors. Significance: Neutrophils are critical contributors to the immunosuppressive microenvironment that restricts the effects of promising immunotherapies in glioblastoma. Our study identifies hypoxia-driven histone lactylation as a potential target to block immunosuppressive neutrophils and boost the effects of immunotherapy in glioblastoma and in other cancer settings beyond brain tumors.

Year:

2025

Year:

2023

BACKGROUND: Paraspinal lumbar schwannomas are primarily located outside of the spinal canal with minimal extension into the neural foramen. Approaching these tumors through a traditional posterior approach can be challenging given their lateral location to the spine and is likely to require extensive bony removal and potential destabilization of the spine. Alternatives approaches have been identified that may circumvent the need for extensive bony removal. OBJECTIVE: To examine the use of the paramedian Wiltse approach for giant extraspinal tumors and compare the approach with other nonposterior approaches. METHODS: We present 2 cases in which the paramedian Wiltse approach is used to effectively approach large paraspinal schwannomas and achieve complete tumor resection without destabilization of the spine. RESULTS: The paramedian Wiltse approach along with expandable retractors systems were able to achieve complete resection of the giant paraspinal schwannomas. Neural preservation was able to be achieved in one case which was facilitated by the exposure achieved through the posterior paramedian corridor that allowed for visualization of the proximal and distal ends of the tumor. CONCLUSION: The paramedian Wiltse approach is an ideal approach to target large extraspinal schwannomas for complete resection and potential neural preservation without the need for destabilization of the spine.

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (19)

Jongmyung Kim

Assistant Professor

University of South Florida

UNITED STATES
View details

Qi Zhang

University of Western Ontario

CANADA
View details

Sheila K. Singh

McMaster University

CANADA
View details

Alessandra De Leo

The Wistar Institute

UNITED STATES
View details

Charles Swanton

Chief Clinician

-

UNITED KINGDOM
View details

michela perego

Research Assistant Professor

The Wistar Institute

UNITED STATES
View details

Jason Moffat

Senior Scientist and Program Head

Hospital for Sick Children

CANADA
View details

Ariana Huebner

University College London

UNITED KINGDOM
View details

Filippo Veglia

Assistant Professor

The Wistar Institute

UNITED STATES
View details

Jian‐Qiang Lu

Neuropathologist

McMaster University Faculty of Health Sciences

CANADA
View details

Blessing Bassey-Archibong

Assistant Professor

Concordia University of Edmonton

CANADA
View details

aurelia rughetti

Associate Professor

Sapienza University of Rome

ITALY
View details

Jose Conejo-Garcia

Duke Science and Technology Scholar

Duke Medicine

UNITED STATES
View details

Kui Zhai

McMaster University

CANADA
View details

Shawn Li

Professor

Western University

CANADA
View details

Paulo Rodriguez

Senior Member-Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Antoine Dufour

Professor

University of Calgary

CANADA
View details

Shawn Chafe

Research Associate

McMaster University

CANADA
View details

Xiaoqing Yu

Associate Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details